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Abstract
Background: An intrachromosomal amplification of chromosome 21 (iAMP21) defines a unique subgroup of B-cell
precursor acute lymphoblastic leukemia (BCP-ALL). The finding of three or more extra copies of the RUNX1 gene
by fluorescence in situ hybridization (FISH) is internationally used to define an iAMP21. Genomic profiling of
chromosome 21 has been suggested for assisting diagnostic case identification. Due to limitations of comparative
genomic hybridization, in terms of a routine application as first line-screening tests we evaluated the multiplex
ligation-dependent probe amplification (MLPA) SALSA P327_A1 and P327_B1 probe sets for detecting chromosome
21 copy number alterations in Brazilian childhood BCP-ALL.
Results: In 74 out of 368 patients gain of genetic material was detected. For data confirmation RUNX1 directed
FISH was performed. Cells with ≥5 RUNX1 signals (n = 9) were considered as “true iAMP21” while <5 RUNX1 signals
(n = 41) were counted as evidence for additional copies of intact chromosomes 21. All patients with an iAMP21
had high MLPA peak ratios (≥1.8), while the majority of patients with <5 RUNX1 presented low MLPA peak ratios
(<1.8). Observed differences gained statistical strength by comparing probes located within the common region
of amplification. Next, a principal component analysis was performed in order to illustrate distribution of cases
according to their MLPA peak profile in two dimensions. Cases with an iAMP21 mostly clustered together,
however additional cases with <5 RUNX1 signals or no available FISH data located in proximity.
Conclusions: MLPA qualified as a high throughput technique that could be employed in future studies for a
critical comparison with data obtained by FISH, especially in cases where metaphase nuclei are not available.
Taking submicroscopic aberrations into account examined by MLPA, cases exhibiting an “iAMP21 like” peak ratio
profile but <5 RUNX1 signals should be considered as candidates for this chromosomal abnormality.
Keywords: B-cell precursor acute lymphoblastic leukemia (BCP-ALL), Intrachromosomal amplification of
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Background
Cytogenetic and molecular studies have displayed among
B-cell precursor-acute lymphoblastic leukemia (BCP-ALL)
a distinct subtype, characterized by an intrachromosomal
amplification of chromosome 21 (iAMP21) [1, 2].
Patients with an iAMP21 treated under standard risk
regimens had an elevated relapse rate and a dismal prog-
nosis compared to other BCP-ALL, hence risk directed
treatment intensification has been recommended [3–7].
Amplification of 21q has also been found in other hemato-
poietic malignancies such as acute myeloid leukemia
and disorders with complex karyotypes involving chromo-
some 21, supporting the hypothesis that gains within
chromosome 21 interplay with the function of a specific
set of genes [8]. Array based genomic analyses revealed
that alterations on chromosome 21 are highly complex
and suggested to arise from breakage-fusion bridge cycles
followed by chromothripsis and other complex structural
rearrangements on chromosome 21 [9–11]. Multiple
regions of gains, amplifications, inversions and deletions
with a high level of individuality between different pa-
tients have been described. Patients exhibited a com-
mon region of amplification (CRA, covering a region
of 6 MB) as well as in most cases a common region
of deletion (CRD, covering a region of 9 MB) [10]. The
CRA, located between 32.8-37.9 MB on chromosome 21,
consistently showed the most amplified as well as over-
expressed regions, encoding for genes that play important
roles in leukemia such as RUNX1, DYRK1A and ETS2 [11].
The method nowadays internationally recommended to
identify an iAMP21 is fluorescence in situ hybridization
(FISH) using probes directed to the Runt Related
Transcription Factor 1 (RUNX1) gene, present by three
or more extra copies on a single abnormal chromosome
21 [10, 12]. However, case interpretation needs to be done
cautiously, particularly whenever FISH was performed
from interphase nuclei because additional copies of the
RUNX1 genes are also present in high hyperdiploid
karyotypes. In light of such considerations, genomic
analyses of chromosome 21 might be taken into account
for confirming the accuracy of iAMP21 diagnosis [13].
Multiplex ligation-dependent probe amplification (MLPA)
assays represent a quick and cost effective alternative to
array based techniques allowing screening of large cohorts
for sub microscopic copy number changes. By quantifica-
tion of multiple gene sequences on multiple sites on a
previously defined chromosomal region such as an
abnormal chromosome 21 it permits data comparison
with other molecular techniques [14].
In this work, we evaluated MLPA for detecting an
iAMP21 in a cohort of Brazilian childhood BCP-ALL and
compared data with those obtained from FISH, convention-
ally detecting RUNX1 copy numbers. To our knowledge,
this is the first published report where the SALSA MLPA
P327_A1 and P327_B1 probe sets were tested in order to
identify copy number alterations (CNAs) in a subset of
genes, demonstrating its value as a tool for screening large
cohorts of patients.
Results
Demographic and clinical characteristics of 368 BCP-ALL
alleged according to designated criteria with the MLPA
results are shown in Table 1. Most variables were equally
distributed in negative and positive cases, but age between
2-10 years, common-ALL and standard prognostic risk
was more prone in MLPA positive patients (p < 0.05).
Blast cell counts were similar in both groups with an
average of 82 % (range 67 % to 90 %) in the whole cohort.
Table 1 Baseline characteristics of BCP-ALL with and without
chromosome 21 CNAs
Characteristics MLPA negative MLPA positive P-value
n (%) n (%)
Total 294 (80.0) 74 (20.0)
Gender
Male 169 (57.0) 42 (56.8)
Female 125 (43.0) 32 (43.2) 0.999
Age range, (years)
≤1 15 (5.1) 0 (0.0)
2-10 185 (62.6) 62 (83.8)
>10 94 (32.3) 12 (16.2) 0.001**
Skin color
White 117 (42.5) 36 (50.0)




≤20 153 (52.8) 40 (54.8)
20-50 56 (19.3) 15 (20.5)
>50 81 (27.9) 18 (24.7) 0.816
Immunophenotype
Pro-B ALL 31 (10.5) 1 (1.4)
Common-ALL 205 (69.8) 58 (78.3)
Pre-B ALL 58 (19.7) 15 (20.3) 0.038*
NCI risk group
Standard risk 141 (48.3) 46 (63.0)
High risk 151 (51.7) 27 (37.0) 0.018*
Status
Alive 28 (65.1) 21 (75.0)
Dead 15 (34.9) 7 (25.0) 0.379
n number, WBC white blood cell count x109/l
*p < 0.05; **p ≤ 0.01
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Patient material was first subjected to MLPA using the
SALSA MLPA P327_A1 probe set. Relative peak heights
between 0.75 and 1.3 were considered normal, while
those below 0.75 and above 1.3 indicated losses or gains
of genomic material, respectively (Fig. 1). Two hundred
and ninety-four patients had no copy number changes of
chromosome 21 regions since test fragments binding
on chromosome 21 and control fragments binding on
other chromosomes appeared normal, whereas in 74
patients gain of genetic material on chromosome 21 was
found. None of our patients harbored gene deletions on
chromosome 21.
For data validation and sub-division of MLPA positive
patients we next applied the SALSA MLPA P327_B1 probe
set. Down syndrome (DS) patients and cytogenetically
confirmed hyperdiploid ALL with extra copies of chromo-
somes 21 (Hyp + 21) were included as additional controls.
We could not re-evaluate all 74 cases with chromosome 21
CNAs due to restrictions in the availability of DNA.
However, for those patients subjected to analysis, no
qualitative differences have been observed (n = 64);
the presence or absence of CNAs on chromosome 21
has been confirmed. Pearson’s correlation coefficients
(r = 0.09101, r2 = 0.8287, p < 0.0001), calculated to measure
Fig. 1 Representative MLPA data shown as screen shots from the Gene-Marker 2.2.0 analysis software. a. MLPA electropherograms of cord blood
(CB) DNA (upper panel) compared to DNA from P4 (lower panel). Differences in peaks heights suggest altered dosages of corresponding exons
depicted below. b. MLPA scatter plots for CB DNA (left panel) compared to P4 DNA (right panel). Reference probes (blue points) and test probes
(green points) are within the normal range (located between green lines) for the CB sample, while test probes (red points) appear elevated for P4
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the linear dependence of variables and Kappa tests
(κ = 0.661, SE = 0.083, 95 % CI = 0.498-0.825) to evaluate
the number of observed agreements revealed only minor
differences between average peak heights obtained from
P327_A1 and P327_B1 probe sets (Fig. 2).
In order to understand gene CNAs distributions, MLPA
results were illustrated in a heat map and arranged from
centromeric to telomeric positions. MLPA peak heights
allocated patients with chromosome 21 abnormalities into
3 main groups by a hierarchical clustering analysis (Fig. 3).
Group 1 (bottom, n = 8) consisted of patients with slightly
elevated MLPA peak ratios clustering in proximity to
BCP-ALL without chromosome 21 CNAs; group 2
(middle, n = 15) of patients with intermediate peak ratios -
similar to those observed in DS and Hyp + 21 - and, group
3 (top, n = 26) of patients with high or very high MLPA
peak ratio profiles. Patient (P) 5 did not allocate into
any of the three groups since its MLPA peak pattern
demonstrated a higher variability than others.
According to availability of material FISH directed to
the RUNX1 gene was performed in 50 patients. Six
patients had a normal FISH pattern with 2 signals of
RUNX1; in 35 patients 3–4 signals for RUNX1 - while in 9
patients ≥5 signals for RUNX1 were observed (Fig. 4a).
Cells with 2–4 RUNX1 signals most likely acquired one or
two additional copies of chromosome 21 (even though
not detectable in all cases by interphase FISH), while
those with ≥5 RUNX1 signals fulfilled the internationally
adopted criteria for an iAMP21.
Patients with an iAMP21 had a mean age of 55 months
(range 22–120) and a median WBC (white blood cell count)
of 15.9 x 109/l (range 7.2-92.0). According to National
Cancer Institute (NCI) risk classification criteria, P5, P6 and
P9 (33,3 %) allocated to the high risk group. P1, P3, P4 and
P5 remained in complete remission until the last follow up
in November 2014, while P8 and P9 succumbed to disease.
For P2, P6, and P7 no follow up data was available.
For data comparison of the methodologies MLPA and
FISH patients were clustered according to the number
of RUNX1 signals (Fig. 4b). Mean MLPA peak ratios and
standard deviations for chromosome 21 probes are
provided in Additional file 1. MLPA peak ratios and in
particular those of CRA genes separated cases with ≥5
RUNX1 signals from cases with 2–4 RUNX1 signals. In
the latter group these were lower and in the same magni-
tude as controls such as patients with DS (PT1-5) and
Hyp + 21 (PH1-3) (Fig. 4c). We next performed a principal
component analysis in order to illustrate the distribution
of cases according to their MLPA peak profile. Patients
were grouped into (1) FISH confirmed iAMP21, (2) <5
RUNX1 signals, (3) no FISH data, (4) DS and Hyp + 21,
and (5) no chromosome 21 aberrations (Fig. 5). Sixty-
three out of sixty-eight patients segregated into three
clusters: The first one consisted of all patients from
group 1 and two patients from group 3 and 4; the
second of all patients from group 4 and most of the
patients of group 2; and the third one of all patients from
group 1 except P5. Interestingly, the latter cluster also con-
tained some patients of group 2 and group 3 that located in
close proximity to patients with an iAMP21; in other words
exhibited an “iAMP21 like” MLPA peak profile.
Since we observed variations in MLPA peak heights
between different patients, the correlation between RUNX1,
DYRK1A, ETS2 and ERG gene load and expression was
tested. Delta threshold cycle (dCT) values for each patient
are shown in Table 2. For illustration we stepwise arranged
cases from the lowest to the highest MLPA mean peak
ratios and depicted corresponding dCT values (Fig. 6).
Positive correlation between the MLPA mean peak ratios
and dCT values were observed, since those patients with
high MLPA mean peak ratios were the ones with low gene
expression. This observation particularly held true for the
genes RUNX1, DYRK1A, and ERG.
Discussion
In this study, we evaluated MLPA as a tool to detect an
iAMP21 in a cohort of BCP-ALL, providing first data of
this leukemia entity in a Brazilian BCP-ALL cohort.
The information about gene CNA distributions on
chromosome 21 was re-tested. Nine out of 368 BCP-ALL
patients (2.4 %) were identified with an iAMP21 according
to criteria specified recently [13]. Taking submicroscopic
aberrations into account examined by MLPA, additional
cases presenting high MLPA peak ratios of genes within
the CRA region or exhibiting an “iAMP21 like” peak ratio
profile of chromosome 21 genes might be considered as
positive for this chromosomal abnormality and subjected
to further genomic tests.
Fig. 2 Pearson’s correlation coefficient analysis of data obtained
from SALSA MLPA P327_A1 and P327_B1 probe sets. MLPA mean
peak ratios over all chromosome 21 probes (black circles) were
plotted for each patient; the black line depicts the linear correlation
of data. Pearson correlation coefficients (r), r-squared (r2)
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In the past 10 years MLPA was successfully applied as
a tool in cancer research, providing precise information
on increased or decreased copy numbers at specific loci
[14]. More recently it has been proven as accurate
and sensitive for detection of CNAs in hematological
malignancies, particularly appearing advantageous for
analyzing large sample sets in a time efficient fashion
[15, 16]. MLPA demonstrated comparable detection
rates to routine interphase FISH for aberrations being
typically present in leukemia. Since it can detect also
rare chromosomal aberrations it was suggested being
applied as an initial test if routine cytogenetics is not
possible or informative [17]. The SALSA P327_A1 and
P327_B1 probe sets were designed to provide information
on the copy number status of 24 and 29 genes located on
chromosome 21, respectively. Six of the 31 probes
targeting chromosome 21 are specific for RUNX1 gene
being located within the CRA. Other probes anneal to
Fig. 3 Hierarchical clustering of patients with and w/o chromosome 21 CNAs, DS and Hyp + 21 controls (n = 68). Data is arranged horizontally from
centromeric to telomeric positions on chromosome 21 and vertically according to similarities in the MLPA peak ratio pattern (hierarchical clustering)
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regions flanking the RUNX1 gene described being dupli-
cated or amplified in most cases with an iAMP21. In our
hands low MLPA mean peak ratios within the CRA (<1.8)
ruled the presence of an iAMP21 out, in all of these cases
less than three additional RUNX1 signals have been
detected. By contrast, high MLPA mean peak (≥1.8) ratios
should be taken as evidence for the presence of an
iAMP21, even though encountering difficulties to detect
this chromosomal abnormality by FISH performed from
interphase preparations. Nevertheless, we cannot rule out
that MLPA in some cases fails to accurately distinguish
between BCP-ALL with 4 copies of a chromosome 21 and
an iAMP21 due to certain variability between blast counts
of different patient samples. On the other hand interphase
FISH could not detect additional RUNX1 signals in a total
of six cases, shown to have gain of genetic material by
Fig. 4 Subdivison of patients with CNAs of chromosome 21 by RUNX1 directed FISH. a. Interphase FISH detecting ETV6 (red) and RUNX1 (green)
alleles from patients with elevated MLPA peak ratios. The number of RUNX1 signals was counted as evidence to differentiate between BCP-ALL
with additional copies of chromosome 21 (left; middle; 3–4 signals) and an iAMP21 (right; ≥5 signals). b. Heat map plotting MLPA peak ratios
obtained from the P327_B1 probe set. Depicted are patients with 2–4 RUNX1 signals (n = 31), ≥5 RUNX1 signals (n = 8), no available FISH data
(n = 10), DS and Hyp + 21 controls (n = 8) as well as normal MLPA peak ratios (n = 12). The scale from Fig. 3 was applied. c. Scatter plot diagrams
showing mean peak ratios of patients in annotated groups over all chromosome 21 probes (left) and CRA probes (right). Dashed lines illustrate
mean values of each patient group. *, P < 0.05; ***, **, P < 0.01; ***, P < 0.001 (unpaired t-test, two tailed)
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MLPA. Even though we are aware of such methodological
pitfalls, these cases unlikely harbored an iAMP21 since
peak ratios obtained from both data sets were low to
intermediate. Further investigation of such cases by
whole genome techniques such as array based com-
parative genomic hybridization or, alternatively exome
sequencing capable of assessing gene copy numbers
would be desirable.
Depending on the chromosomal location of genes,
MLPA peak ratios appeared heterogeneous in BCP-ALL
with an iAMP21. The highest MLPA peak ratios and
lowest variations between different patients were encoun-
tered within and close to the CRA while peak ratios often
dropped towards telomeric regions. These observations
are in line with the view that chromosome 21 aberra-
tions in BCP-ALL with an iAMP21 are highly complex,
exhibiting a stepwise increase in copy numbers towards
the CRA and decrease of copy number towards the CRD,
mapping centromeric and telomeric parts of chromosome
21, respectively [10].
Due to the lack of studies identifying individual genes,
playing an important role in leukemogenesis or providing
evidence that de-regulation of certain candidates would
explain the poor outcome of patients with an iAMP21, the
effect of gene load on mRNA expression within the CRA
was also evaluated. In contrast to our expectations, this
analysis revealed that patients with lowest gene dosages of
RUNX1, DYRK1A, ETS2 and ERG genes displayed the
highest expression of the respective mRNA. These results
need to be consolidated analyzing more patients. As part
of a study to describe genomic alterations and gene
expression in BCP-ALL with an iAMP21, Strefford et al.
2006 evaluated the expression of genes located in the
CRA of eight cases and compared data with that of other
BCP-ALL subtypes. Even though expression levels of the
genes contained within the CRA were higher in BCP-ALL
with an iAMP21 for almost half of the probe sets from the
CRA no over-expression was observed, including the
RUNX1 gene. The authors concluded that these results
could be explained by regulatory mechanisms such as
epigenetics and biofeedback in BCP-ALL [9]. Strikingly,
hyperdiploid leukemias, by definition harboring less gene
copies on chromosome 21 than cases with an iAMP21,
showed higher mRNA expression for the genes analyzed.
Conclusions
Altogether, we confirmed that aberrations on chromo-
some 21 in BCP-ALL with an iAMP21 represent a high
level of complexity but as a group exhibited similar MLPA
peak ratio profiles and, furthermore provided evidence for
Fig. 5 Principal component analysis of grouped patients. Individuals are distributed according to similarities in their MLPA peak ratio profiles and
depicted by color-coded circles that designate certain patient groups. Red Circles demonstrate the presence of three main clusters
Table 2 RT-qPCR data of patients with an iAMP21 for selected
genes located in the CRA
# dCT DYRK1A dCT ERG dCT ETS2 dCT RUNX1
P1 8.715 1.790 0.555 5.950
P2 11.625 7.655 6.430 12.195
P3 3.995 1.775 1.760 3.515
P4 7.885 5.380 4.155 7.250
P5 9.905 7.230 6.200 12.595
P6 9.815 6.665 6.200 11.095
P7 8.420 6.765 3.895 9.630
P8 11.010 5.635 4.845 11.000
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the existence of gene regulatory mechanisms that might
modulate the expression of amplified genes. MLPA
profiles of CRA genes might be taken into account to
facilitate diagnosis whenever metaphase nuclei for FISH
are not available. However, for identification of an iAMP21
solely by MLPA next generation probe sets would need to
include control fragments binding genes on chromosomes
usually over-represented in hyperdiploid ALL.
Methods
Patients
A series of consecutive diagnostic samples from Brazilian
childhood BCP-ALL patients collected between the years
2002 to 2012 were selected according to availability of
material of good quality providing that bone marrow
aspirates harbored at least 30 % of blast cells. The initial
dataset contained samples from 606 patients. Out of
those, 368 samples were retained for this study, excluding
238 cases based on the available results of mutually exclu-
sive gene fusions (ETV6/RUNX1, TCF3/PBX1, MLL-r and
BCR-ABL1). In addition five patients with ALL and Down
syndrome were included.
As criteria for assigning as standard-risk or high-risk
patients, age at diagnosis and WBC according to the
Cancer Therapy Evaluation Program of the NCI were
considered. Data collection and laboratory procedures
have been evaluated and approved by the Research
Ethics Committee from the National Cancer Institute
(INCA) in Rio de Janeiro (CEP #005/06 and CAAE
626.268 at April 28, 2014). Informed consent was obtained
from all subjects or their parents in accordance with the
Declaration of Helsinki.
Multiplex ligation-dependent probe amplification
The presence of an iAMP21 has been evaluated apply-
ing the MLPA SALSA P327_A1 (lot A1-0101) and
P327_B1 (lot B1-0613) probe sets (MRC Holland,
Amsterdam, The Netherlands). Tests fragments have
been designed to evaluate the copy number status of
genes distributed from centromeric to telomeric regions
(q11.2-q22.3, 14.668-46.356) of chromosome 21. The
P327_B1 probe set represents a modified version of the
P327_A1 probe set in which 12 new probes for the
ERG gene and 3 additional probes for chromosome 21
genes have been added. Four RUNX1 specific probes
(exon 10; 7; 6 and 4b) have been replaced while two
probes (exon 9 and 2) remained unchanged. The size
and location of most other test probes as well as
reference probes has been redefined. Detailed infor-
mation about P327_A1 and P327_B1 MLPA probe sets
was downloaded from the MRC Holland website
(http://www.mlpa.com); see Additional files 2 and 3,
respectively. MLPA and capillary electrophoresis based
amplification product separation (ABI 3130xl, Life
Technologies, Carlsbad, CA) was performed according
to the manufacturer’s instructions. Relative copy numbers
were obtained after normalization of peaks against cord
blood derived controls. Sequences were analyzed by the
Gene Marker 2.2.0 software (Soft Genetics LLC, State
College, PA).
Fluorescence in situ Hybridization (FISH)
FISH was performed using the “LPH012 TEL/AML1
Translocation, Dual Fusion Probe”, designed to detect
the TEL/AML1 fusion gene. Cells were processed
Fig. 6 Correlation of MLPA mean peak ratios and gene expression in patients with an iAMP21. Scatter plots demonstrate the relation between
mean MLPA peak ratios and mRNA expression of genes located within the CRA. Each circle represents data of one individual. Similarities between
variables are depicted by linear regression (lines), Pearson correlation coefficients (r) and p-values
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according to the protocols instructions (Cytocell,
Cambridge, UK). Cases were considered positive for an
iAMP21 when ≥5 RUNX1 signals were observed in at
least 7 % of metaphase nuclei (standard deviation +/−
2 %). If metaphase FISH was not possible, an iAMP21
was identified as multiple copies of RUNX1 in most
interphase nuclei [1, 13].
Reverse trancriptase quantitative (RT-q)PCR
Total RNA was isolated by Trizol reagent (Life
Technologies, Carlsbad, CA) and used for cDNA
synthesis by Super Script II Reverse Transcriptase
(Life Technologies, Carlsbad, CA). RUNX1, ETS2,
DYRK1A, ERG and, GAPDH transcripts used as an
endogenous control were quantified by SYBR-green
RT–qPCR (Bioline, London, UK) using the Applied
Biosystems 7300 Real-Time PCR System (Applied
Biosystems, Foster City, CA). For data depiction dCT
values (CT target – CT reference) of biological repli-
cates were calculated. The following primer combinations




forward 5'- TGTAACCCCAAACGCAGTG-3', reverse
5'- ACCGATAAAAGCGACTCTGAA-3'; ERG, forward
5'-AAGTAGCCGCCTTGCAAAT-3', reverse 5'-GTGC




Statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS), 18 (Chicago, IL),
Graph Pad Prism 4.02 (La Jolla, Ca) and R (Foundation
for Statistical Computing, Auckland, New Zealand) soft-
ware packages. Confidence intervals of 95 % were used;
P-values <0.05 were considered statistically significant.
Chi-square and Fisher’s exact tests were used for com-
parative variable analyzes of demographic and clinical
variables. Correlation and the strength of agreement
between MLPA data were assessed by Pearson correl-
ation coefficients and Kappa tests, respectively. Hier-
archical clustering and principal component analyses
(PCA) were created in R. For creation of heat maps
MLPA values were scaled and centered using the scale
function followed by clustering and plotting of normal-
ized values using heat map .2 with default values.
Patient groups from heatmaps were compared by un-
paired, two sided Student’s T-tests. PCA was performed
on scaled values using the prcomp() function with
default parameters.
Additional files
Additional file 1: Mean MLPA peak ratios in BCP-ALL obtained
from test fragments of the MLPA SALSA P327-B1 probe set.
Additional file 2: The size and location of each test and reference
fragment of the MLPA SALSA P327_A1 probe set.
Additional file 3: The size and location of each test and reference
fragment of the MLPA SALSA P327_B1 probe set.
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